Untenable Dosing: A Common Pitfall of Modern DLT-targeting Phase I Designs in Oncology

Por Frankel, Paul H., Chung, Vincent, Xing, Yan, Longmate, Jeff, Groshen, Susan, Newman, Edward M.
Publicado no Curr Probl Cancer (2020)

A Phase 2 Study of Belinostat (PXD101) in Patients with Relapsed or Refractory Acute Myloid Leukemia or Patients Over 60 with Newly-Diagnosed Acute Myloid Leukemia: A California Ca...

Por Kirschbaum, Mark H., Foon, Kenneth A., Frankel, Paul, Ruel, Christopher, Pulone, Bernadette, Tuscano, Joseph M., Newman, Edward M.
Publicado em 2014

Model of a Queuing Approach for Patient Accrual in Phase 1 Oncology Studies

Por Frankel, Paul H., Chung, Vincent, Tuscano, Joseph, Siddiqi, Tanya, Sampath, Sagus, Longmate, Jeffrey, Groshen, Susan, Newman, Edward M.
Publicado no JAMA Netw Open (2020)

A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors

Por Iqbal, Syma, Lenz, Heinz-Josef, Gandara, David R., Shibata, Stephen I., Groshen, Susan, Synold, Timothy W., Newman, Edward M.
Publicado em 2013

A Phase II study of VEGF Trap (Aflibercept, NSC 724770) in Patients with MDS: A California Cancer Consortium Study

Por Kirschbaum, Mark, Frankel, Paul, Synold, Timothy W., Zain, Jasmine, Claxton, David, Tuscano, Joseph, Newman, Edward M., Gandara, David R., Lara, Primo N.
Publicado no Br J Haematol (2016)

A Phase I Pharmacodynamic Study of GTI-2040, an Antisense Oligonucleotide Against Ribonuclotide Reductase, in Acute Leukemias: A California Cancer Consortium Study

Por Kirschbaum, Mark H., Frankel, Paul, Synold, Timothy W., Xie, Zhiliang, Yen, Yun, Popplewell, Leslie, Chen, Robert, Aljitawi, Omar S., Tuscano, Joseph M., Chan, Kenneth K., Newman, Edward M.
Publicado no Leuk Lymphoma (2016)

Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: a California Cancer Consortium Trial

Por Mohrbacher, Ann M., Yang, Allen S., Groshen, Susan, Kummar, Shivaani, Gutierrez, Martin E., Kang, Min H., Tsao-Wei, Denice, Reynolds, C. Patrick, Newman, Edward M., Maurer, Barry J.
Publicado no Clin Cancer Res (2017)

Oral and intravenous pharmacokinetics of 5-fluoro-2’-deoxycytidine and THU in cynomolgus monkeys and humans

Por Holleran, Julianne L., Beumer, Jan H., McCormick, David L., Johnson, William D., Newman, Edward M., Doroshow, James H., Kummar, Shivaani, Covey, Joseph M., Davis, Myrtle, Eiseman, Julie L.
Publicado no Cancer Chemother Pharmacol (2015)

Phase I Trial of Belinostat in Combination with 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies: A California Cancer Consortium NCI/CTEP Sponsored Trial.

Por Luu, Thehang, Frankel, Paul, Beumer, Jan H, Lim, Dean, Cristea, Mihaela, Appleman, Leonard J, Lenz, Heinz J, Gandara, David R, Kiesel, Brian F, Piekarz, Richard L, Newman, Edward M
Publicado no Cancer Chemother Pharmacol (2019)

A Phase I Study of Intravenous Fenretinide (4-HPR) for Patients with Malignant Solid Tumors

Por Thomas, Jacob S., El-Khoueiry, Anthony B., Maurer, Barry J., Groshen, Susan, Pinski, Jacek K., Cobos, Everardo, Gandara, David R., Lenz, Heinz J., Kang, Min H, Reynolds, C. Patrick, Newman, Edward M.
Publicado no Cancer Chemother Pharmacol (2021)

Pharmcodynamics (PD) and Pharmacokinetics (PK) of E7389 (Eribulin, Halichondrin B Analog) During a Phase I Trial in Patients with Advanced Solid Tumors: A California Cancer Consort...

Por Morgan, Robert J., Synold, Timothy W., Longmate, Jeffrey A., Quinn, David I, Gandara, David, Lenz, Heinz-Josef, Ruel, Christopher, Xi, Bixin, Lewis, Michael D., Colevas, A. Dimitrios, Doroshow, James, Newman, Edward M.
Publicado no Cancer Chemother Pharmacol (2015)

A Phase 1 Trial Dose Escalation Study of Tipifarnib on a Week-On, Week-Off Schedule in Relapsed, Refractory or High-Risk Myeloid Leukemia

Por Kirschbaum, Mark, Synold, Timothy, Stein, Anthony S., Tuscano, Joseph, Zain, Jasmine M., Popplewell, Leslie, Karanes, Chatchada, O'Donnell, Margaret R., Pulone, Bernadette, Rincon, Amalia, Wright, John, Frankel, Paul, Forman, Stephen J., Newman, Edward M.
Publicado em 2011

A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

Por Tuscano, Joseph M., Maverakis, Emanual, Groshen, Susan, Tsao-Wei, Denice, Luxardi, Guillaume, Merleev, Alexander A., Beaven, Anne, DiPersio, John F, Popplewell, Leslie, Chen, Robert, Kirschbaum, Mark, Schroeder, Mark A., Newman, Edward M.
Publicado no Clin Cancer Res (2019)

Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: Comparison of real‐time reverse transcription‐PCR vs. Relative quantification revers...

Por Juhasz, Agnes, Frankel, Paul, Cheng, Catherine, Rivera, Hector, Vishwanath, Reena, Chiu, Alice, Margolin, Kim, Yen, Yun, Newman, Edward M., Synold, Tim, Wilczynski, Sharon, Lenz, Heinz‐Josef, Gandara, David, Albain, Kathy S., Longmate, Jeffrey, Doroshow, James H.
Publicado no J Clin Lab Anal (2003)

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epider...

Por Reckamp, Karen L., Frankel, Paul H., Ruel, Nora, Mack, Philip C., Gitlitz, Barbara J., Li, Tianhong, Koczywas, Marianna, Gadgeel, Shirish M., Cristea, Mihaela C., Belani, Chandra P., Newman, Edward M., Gandara, David R., Lara, Primo N.
Publicado no Front Oncol (2019)

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fuoro-2′-deoxycytidine, administered with tetrahydrouridine

Por Newman, Edward M., Morgan, Robert J., Kummar, Shivaani, Beumer, Jan H., Blanchard, M. Suzette, Ruel, Christopher, El-Khoueiry, Anthony B., Carroll, Mary I., Hou, Jessie M., Li, Chun, Lenz, Heinz J., Eiseman, Julie L., Doroshow, James H.
Publicado no Cancer Chemother Pharmacol (2015)

Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study

Por Shibata, Stephen I., Doroshow, James H., Frankel, Paul, Synold, Timothy W., Yen, Yun, Gandara, David R., Lenz, Heinz-Josef, Chow, Warren A., Leong, Lucille A., Lim, Dean, Margolin, Kim A., Morgan, Robert J., Somlo, George, Newman, Edward M.
Publicado em 2009

Phase 1 study of the aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies

Por Siddiqi, Tanya, Frankel, Paul, Beumer, Jan H., Kiesel, Brian F., Christner, Susan, Ruel, Chris, Song, Joo Y., Chen, Robert, Kelly, Kevin R., Ailawadhi, Sikander, Kaesberg, Paul, Popplewell, Leslie, Puverel, Sandrine, Piekarz, Richard, Forman, Stephen J., Newman, Edward M.
Publicado no Leuk Lymphoma (2019)

A Phase I Trial of Topotecan plus Tivantinib in Patients with Advanced Solid Tumors

Por Liu, Stephen V., Groshen, Susan G., Kelly, Karen, Reckamp, Karen L., Belani, Chandra, Synold, Timothy W., Goldkorn, Amir, Gitlitz, Barbara J., Cristea, Mihaela C., Gong, I-Yeh, Semrad, Thomas J., Xu, Yucheng, Xu, Tong, Koczywas, Marianna, Gandara, David R., Newman, Edward M.
Publicado no Cancer Chemother Pharmacol (2018)

A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

Por Kummar, Shivaani, Ji, Jiuping, Morgan, Robert, Lenz, Heinz-Josef, Puhalla, Shannon L., Belani, Chandra P., Gandara, David R., Allen, Deborah, Kiesel, Brian, Beumer, Jan H., Newman, Edward M., Rubinstein, Larry, Chen, Alice, Zhang, Yiping, Wang, Lihua, Kinders, Robert J., Parchment, Ralph E., Tomaszewski, Joseph E., Doroshow, James H.
Publicado em 2012